CD Markers

Antibodies Targeting CD Markers
bioxcell.com

CD Marker Antibodies
α-mouse CD90.2 (Thy1.2) (BP0066)

α-mouse CD137 (4-1BB) (BP0169)

α-mouse CD152 (CTLA-4) (BP0131)

α-mouse CD4 (BP0003-1)

CD4+ T cells
Control

Relative Cell Number

LOB12.3

CD90.2(20-27 kDa)

Purified CD90.2

Antigen

Reactivity

CD4 (55 kDa)

CTLA-4 (30 kDa)

Log Fluorescence Intensity

Purified CTLA-4

Application

Purified CD4Clone

InVivoMab InVivoPlus
CatalogCatalog

CD1ahumanin vitro CD1a blockade, FC

OKT-6

CD1d (CD1.1)

mousein vivo CD1d neutralization

19G11BE0000
BE0179BE0211CD1d (CD1.1)

mouseiNKT cell neutralization, in vivo CD1d blockade, FC

20H2 (HB323)

CD3

humanin vitro T cell stimulation/activation, in vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC

OKT-3

BE0001-2

CD3

mouse

in vitro T cell stimulation/activation

17A2

BE0002CD3humanin vivo T cell depletion in humanized mice, ex vivo T cell inhibition for xenographs, FC

UCHT1 (Leu-4) (T3)

BE0231

CD3ɛ

mousein vivo T cell depletion, in vitro T cell stimulation/activation, IF, FC

145-2C11BE0001-1

CD3ɛ

mouse

in vitro T cell negative selection, in vitro T cell stimulation/activation, IFKT3BE0261

CD3ɛ F(ab')2 fragment

mouse

in vivo T cell depletion

145-2C11 f(ab')2 Fragments

BE0001-1FAB

CD4

mouse

in vivo CD4+ T cell depletion, FC

GK1.5BE0003-1

CD4

human

in vitro T cell stimulation/activation, in vivo CD4+ T cell depletion in humanized mice, FC, IP

OKT-4BE0003-2

CD4

mouse

in vivo blockade of CD4+ T-cell responses, WB

YTS 177BE0003-3CD4mousein vivo CD4+ T cell depletion

YTS 191

BE0119CD4humanin vitro CD4 blockade, in vitro blocking of CD4+ T cell activation, IF, IHC-F, FC

RPA-T4

BE0288CD4

rat

in vivo CD4+ T cell depletion, FCOX-38

BE0308CD8 (Lyt 2.1)

mouse

in vivo CD8+ T cell depletion, FC

116-13.1 (HB129)

BE0118

CD8α

mouse

in vivo CD8+ T cell depletion, IF, FC

53-6.7BE0004-1

CD8α

human

in vivo CD8+ T cell depletion in humanized mice

OKT-8

BE0004-2

BP0001-1

BP0003-1

BP0004-1

CD8αmousein vivo CD8+ T cell depletion

2.43

BE0061BP0061

CD8α

mouse

in vivo CD8+ T cell depletion

YTS169.4

BE0117BP0117CD8β (Lyt 3.2)

mouse

in vivo CD8+ T cell depletion, in vitro CD8 blockade, IF

53-5.8BE0223

CD11a (LFA-1α)

human

in vitro LFA-1 neutralization

TS-1/22.1.1.13

BE0005

CD11a (LFA-1α)

mousein vivo LFA-1 neutralization

FD441.8BE0005-1

CD11a (LFA-1α)

mousein vivo LFA-1 neutralization, FC

M17/4

BE0006

CD11a (LFA-1α)

human

Functional assays, FC

R7-1

BE0192

CD11b

mouse/humanin vivo CD11b neutralization, ILC2 cell purification, FC

M1/70BE0007

CD16/CD32

mousein vivo and in vitro Fc receptor blocking

2.4G2BE0307

CD18

mouse

in vivo LFA-1 neutralization

M18/2BE0009

CD19

mouse

in vivo B cell depletion, in vivo CD19 neutralization, in vitro B cell negative selection, FC

1D3BE0150

CD19

humanFC, Functional assays, IF, Chimeric antigen receptor construction

4G7BE0281

CD20

mouse

in vivo B cell depletion, WB

MB20-11BE0356

CD20

human/monkey

in vivo B cell depletion in hCD20 Tg mice, IHC-F, IP, FC

2H7BE0276
BE0302

CD20

mouse

FC, WBAISB12

CD22

mouse

in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP

Cy34.1BE0011

CD24

mouse

in vivo administration, IHC-F, IHC-P, IF, FC

M1/69

BE0360

CD25 (IL-2Rα)

mousein vivo regulatory T cell depletion, FC

PC-61.5.3

BE0012

CD25 (IL-2Rα)humanIP, IF

7G7B6BE0014

CD27

mouse

in vivo CD27 stimulation, in vitro CD27 stimulation, IP, FC

RM27-3E5BE0348

CD28

mouse

in vivo CD28 blockade, in vitro T cell stimulation/activation

37.51

BE0015-1

CD28

mouse

in vitro T cell stimulation/activation

PV-1

BE0015-5

CD28

rat

in vitro T cell stimulation/activation, FC

JJ319

BE0040CD28

humanin vitro T cell stimulation/activation

9.3

BE0248CD28

human/monkey

in vitro T cell stimulation/activation, FC, IHC-F, IP

CD28.2

BE0291

CD28

mouse

in vivo and in vitro T cell stimulation/activation

D665

BE0328

CD29

mouse

IF, FCKMI6BE0232

CD32 (FcγRIIA)

human

in vivo FcγRIIA blockade in humanized mice, in vitro FcγRIIA blockade, ELISA, FC

IV.3

BE0224

CD38

mouse

in vivo and in vitro CD38 stimulation, in vitro B cell activation, IFNIMR5BE0317

CD40

mouse

in vivo CD40 activation, in vitro B cell stimulation/activation

FGK4.5/FGK45

BE0016-2

CD40

human

in vitro B cell stimulation, in vitro CD40 stimulation, in vitro macrophage stimulation, Functional assays, FC

G28.5

BE0189

CD154 (CD40L)

mouse

in vivo and in vitro blocking of CD40/CD40L signaling

MR-1

BE0017-1

CD154 (CD40L)

human/monkey

in vitro blocking of CD40/CD40L signaling, in vivo blocking of CD40/CD40L signaling, IP, FC

5C8BE0292

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation

BP0356BP0012BP0016-2
BP0017-1α-mouse CD8α (BP0061)

α-mouse CD40 (BP0016-2)

α-mouse CD152 CTLA-4 (BP0032)
CD4+ T cells

α-mouse CD210 (IL-10R) (BP0050)

ControlCD8α (35 kDa)

Purified CD8α

Antigen

Reactivity

Relative Cell Number

UC10-4F10-11

CD40 (57 kDa)

Purified CD40

IL-10R (31kDa)101102103104Log Fluorescence Intensity

105Application

Purified IL-10RClone

InVivoMab InVivoPlus
CatalogCatalog

CD44mouse/humanin vivo CD44 neutralization

IM7CD44humanin vivo CD44 blockade in xenografts, in vitro CD44 blockade, WB, IF

Hermes-1

CD45RBmouse

in vivo anti-CD45RB–mediated tolerance induction, in vivo pre-mNK cell depletion

MB23G2 (HB220)

BE0019CD45.2mousein vivo and in vitro CD45.2 blockade, FC, IHC-F,

104.2

BE0300CD47

humanin vivo CD47 neutralization in human tumor xenograft models or humanized mice, in vitro CD47 neutralization, FC

B6H12BE0019-1

CD47

human/mouse/rat

in vivo and in vitro CD47 blockade, IFMIAP410

BE0283

CD47 (IAP)

mousein vivo CD47 blockade, in vitro CD47 blockade, IFMIAP301

BE0270BE0039BE0262

CD48

mouse

in vivo and in vitro CD48 blockade

HM48-1

BE0147

CD49d (VLA-4)

mouse/humanin vivo and in vitro VLA-4 neutralization, FC

PS/2

BE0071

CD54 (ICAM-1)

mouse

In vivo ICAM-1 neutralization

YN1/1.7.4

BE0020-1

CD54 (ICAM-1)

humanin vitro T cell stimulation/activation, IF

R6-5-D6BE0020-2CD62E (E-Selectin)

mouse

in vivo and in vitro E-selectin blockade, IHC-F

9A9BE0294

CD62L (L-Selectin)mouse

In vivo CD62L neutralization

Mel-14BE0021

CD69

mouse

in vivo down-regulation of CD69 expression, Functional assays

CD69.2.2

BE0330

CD70

mouse

in vivo and in vitro CD70 blockade, FC

FR70

BE0022

CD71

human

FC, IHC-F

OKT9BE0023

CD71 (TfR)

human

WB, IP, FC

5E9C11BE0343

CD71 (TfR1)

mousein vivo depletion of CD71+ cells

R17 217.1.3/TIB-219

BE0175

CD71 (TfR1)

mousein vivo depletion of CD71+ cells, IF, IHC-F, WB

8D3

BE0329CD71 (TfR1)

rat/mouse

Targeted drug delivery to the brain, IHC-F, FC

OX-26

BE0331

CD73

mouse

in vivo CD73 blockade

TY/23

BE0209CD80 (B7-1)

mouse

in vivo B7-1 blockade, affinity chromatography

1G10

BE0134

CD80 (B7-1)

mouse

In vivo CD80 blockade, FC

16-10A1

BE0024

CD86 (B7-2)

mouse

In vivo CD86 blockade, FC

GL-1

BE0025

CD90 (Thy1)

mousein vitro T cell depletion

M5/49.4.1

BE0076

CD90.1 (Thy1.1)

mouse

in vivo T cell depletion

19E12BE0214

CD90.2 (Thy1.2)

mouse

in vivo ILC depletion, in vivo T cell depletion

30H12BE0066

CD91 (LRP1)

mouse/human/rat

WB, IF, IP

11H4BE0333

CD96

mouse

in vivo and in vitro CD96 blocking, FC

3.3

BE0337

CD103

mouse

In vivo CD103 neutralization, IF, FC

M290

BE0026

CD106 (VCAM-1)

mousein vivo VCAM-1 neutralization, IF

M/K-2.7

BE0027

CD115 (CSF1R)

mouse

in vivo macrophage depletion, in vivo monocyte depletion, in vitro CSF-R1 neutralization, FC

AFS98

BE0213

CD115 (CSF1R)

humanin vitro CSF1R neutralization, IHC-P, FC, Functional assays

2-4A5-4BE0347

CD117 (c-Kit)

mouse

FC, IF, IHC

2B8BE0280

CD119 (IFNγR)

mousein vivo IFNγR neutralization

GR-20BE0029

CD119 (IFNγRα)mouse

WB, IP, FC

2E2

BE0287

CD120b (TNFR2)

mouse

in vivo TNFR2 blockade, in vitro TNFR2 blockade

TR75-54.7

BE0247

CD121a (IL-1 R)

mousein vitro IL-1 R blockade

JAMA-147

BE0256

CD122 (IL-2Rβ)mousein vitro NK cell negative selection, IP, FC

5H4BE0272

CD122 (IL-2Rβ)mousein vivo NK cell depletion, in vitro IL-2R blockade, Functional assays, FC

TM-Beta 1

BE0298

CD127 (IL-7Rα)

mousein vivo blocking of IL-7Rα signaling, FC

A7R34

BE0065

CD132 (common γ chain)mousein vivo γc blockade, Functional assays, IP, FC

3E12BE0271

CD134 (OX40)

mouse

in vivo and in vitro OX40 activation

OX-86

BE0031

CD134L (OX40L)

mouse

in vivo blocking of OX40/OX40L signaling, in vitro OX40L neutralization

RM134L

BE0033-1

BP0283BP0066BP0213BP0031

CD137 (4-1BB)

mousein vivo activation of 4-1BB

LOB12.3

BE0169BP0169CD137 (4-1BB)

mousein vivo and in vitro 4-1BB stimulation

3H3BE0239

BP0239CD137 (4-1BB)

mouse

in vitro 4-1BB blockade, FC

17B5

BE0296

CD137L (4-1BBL)

mousein vivo 4-1BBL blockade

TKS-1

BE0110CD152 (CTLA-4)

mouse

in vivo and in vitro CTLA-4 neutralization, FC

UC10-4F10-11BE0032BP0032

CD152 (CTLA-4)

mouse

in vivo and in vitro CTLA-4 neutralization, FC

9H10

BE0131

BP0131

CD152 (CTLA-4)

mouse

in vivo CTLA-4 neutralization

9D9BE0164

BP0164| FC Flow cytometry (requires flurochrome conjugation)

Antibodies for in vivo research since 1997.

α-mouse CD309 (VEGFR-2) (BP0060)

α-mouse CD134 (OX40) (BP0031)
purity level

InVivoMab vs. InVivoPlus
InVivoMabInVivoPlus< 2EU/mg< 1EU/mg

> 95%

> 95%

protein aggregates validated at ≤ 5%

VEGF-2 (152 kDa)

azide and carrier protein free
OX40 (40kDa)

endotoxin concentration
validated by immunoblot, FC, or ELISA
tested for murine pathogens

Purified VEGF-2

Antigen

Reactivity

Purified OX40

available in bulk quantities

ApplicationClone

CD152 (CTLA-4)

humanin vitro CTLA-4 neutralization, FC

BN13

CD159 (NKG2A/C/E)

mouse

in vivo and in vitro NKG2A blockade, IHC-F, FC

20D5

InVivoMab InVivoPlus
CatalogCatalog
BE0190BE0321

CD161 (NK1.1)

mouse

in vivo NK cell depletion, FC

PK136

BE0036

CD162 (PSGL-1)

mousein vivo PSGL-1 blockade, IHC-F

4RA10

BE0186

CD172a (SIRPα)mousein vivo and in vitro SIRPα blocking, WB, IP, FC

P84

BE0322

CD178 (FasL)

mouse

in vivo and in vitro FasL blockade, Functional assay, IHC-P, FC

MFL3

BE0319CD183 (CXCR3)

mouse

in vivo CXCR3 neutralization, FC

CXCR3-173

BE0249

CD193 (CCR3)

mousein vivo eosinophil depletion

6S2-19-4

BE0316

CD200 (OX2)

mousein vivo and in vitro CD200 blockade, IHC-F, IF, FC

OX-90

BE0299CD209b (SIGN-R1)

mousein vivo SIGN-R1 blockade, IHC-F, WB, FC

22D1

BE0220CD210 (IL-10R)

mouse

in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, FC

1B1.3A

BE0050CD220 (Insulin Receptor)

humanWB

IR 83-22

BE0338BE0174

CD223 (LAG-3)

mousein vivo and in vitro LAG-3 neutralization, FC

C9B7W

CD227 (MUC1)

humanin vivo administration in mouse xenograft models, in vitro cell cytotoxicity assay, WB, IHC-P, IF,C595 (NCRC48) BE0336

CD243 (MDR-1)

human/monkey

in vivo MDR-1 blocking/depletion in xenogeneic murine tumor models, in vitro MDR-1 blocking, IHC-P

UIC2

BE0340CD254 (RANKL)

mousein vivo RANKL blockade

IK22/5

BE0191

CD262 (DR5)mousein vivo and in vitro induction TRAIL-mediated apoptosis

MD5-1

BE0161

CD272 (BTLA)

mousein vivo BTLA stimulation, in vivo BTLA blockade

6A6BE0132

CD272 (BTLA)

mousein vivo and in vitro stimulation of BTLA, FC

PK18.6

BE0153

CD272 (BTLA)

mousein vivo BTLA blockade, in vitro T cell stimulation/activation, FC

PJ196

BE0196

CD272 (BTLA)

mouse

in vivo BTLA+ B cell and CD4 T cell depletion, FC

6F7BE0304

CD273 (PD-L2)

mousein vivo and in vitro PD-L2 blockade, IHC-F, FC

TY25

BE0112

CD274 (PD-L1)

mousein vivo PD-L1 blockade, IF, IHC-F, FC

10F.9G2

BE0101CD275 (ICOSL)

mousein vivo ICOSL neutralization

HK5.3BE0028CD276 (B7-H3)

mousein vivo B7-H3 blockade, FC

MJ18BE0124

CD278 (ICOS)

mousein vivo blocking of ICOS/ICOSL signaling, FC

7E.17G9

BE0059BP0036BP0050BP0174BP0101

CD279 (PD-1)

mouse

in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization

J43

BE0033-2

BP0033-2

CD279 (PD-1)

mouse

in vivo blocking of PD-1/PD-L signaling

RMP1-14BE0146BP0146

CD279 (PD-1)

humanin vitro PD-1 neutralization, in vivo PD-1 blockade in humanized mice

J116

BE0188

CD279 (PD-1)

humanin vivo PD-1 blockade in humanized mice, FC

J110

BE0193

CD279 (PD-1)

mouse

in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC, WB

29F.1A12

BE0273

CD314 (NKG2D)

mouse

in vivo and in vitro NKG2D blockade, FC

CX5BE0334

CD317 (BST2, PDCA-1)

mousein vivo pDC depletion, IF, FC

927

BE0311

CD324 (E-Cadherin)mouse

in vivo E-Cadherin neutralization, in vitro E-Cadherin neutralization, IF, IP, WB

DECMA-1

BE0352

CD326 (EpCAM)

mouse

WB, IF, IHC-F, FC

G8.8

BE0346

CD340 HER2 (neu)human/rat

in vivo and in vitro HER2/neu inhibition, IP, IF, FC

7.16.4

BE0277

CD365 (TIM-1)

mousein vivo TIM-1 neutralization

RMT1-10BE0113

CD366 (TIM-3)

mousein vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC

RMT3-23

BE0115

CD366 (TIM-3)

mousein vivo TIM-3 neutralization, in vitro TIM-3 blocking, FC

B8.2C12BE0275

CD370 (CLEC9A)

mouse

in vivo Ag targeting to CLEC9A+ DCs, WB, ELISA, IP, IF, FC

7H11BE0305

BP0273BP0115

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires flurochrome conjugation)

For over 20 years, scientists have trusted Bio X Cell as their go-to source for in vivo functional grade antibodies. This is reflected in over 15,000
peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed toproducing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.
Bio X Cellbioxcell.com | 1.866.787.3444
customerservice@bioxcell.com
Conditions: For Research Use Only. Not for use in diagnostic or theraputic procedures. Not for resale.
Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell. © 2021 Bio X Cell